Trinity Hall, Cambridge

Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology

Retrieved on: 
星期四, 九月 28, 2023
Medicinal chemistry, Swiss, Swiss Federal Institute of Technology, Drug development, University, Therapy, ETH, Cancer, Research, Doctor of Philosophy, Trinity Hall, Cambridge, Chemistry, Entrepreneurship, Flagship Pioneering, Patient, Fellow, European Research Council, Atomic mass, Chemical biology, Library, Royal Society, Federal Institute for Materials Research and Testing, Pharmaceutical industry, Fine chemical, Nursing, Spexy Beast

Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology

Key Points: 
  • Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
    Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
    Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company has appointed Gonçalo Bernardes, PhD, as acting Head of Chemical Biology.
  • “We are thrilled to welcome Gonçalo to Spexis, where we look forward to leveraging his expertise in chemical biology to advance the development of our novel macrocycle pipeline,” said Jeff Wager, M.D., Chairman & CEO of Spexis.
  • “Spexis remains committed to strengthening our leading position in macrocycle-based therapeutics with our two distinct and well characterized libraries, PEMFinder and MACROFinder.
  • Spexis continues to leverage its macrocycle platform into new therapeutic modalities and the company expects to provide further details on their progress later this year.

Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology

Retrieved on: 
星期四, 九月 28, 2023
Medicinal chemistry, Swiss, Swiss Federal Institute of Technology, Drug development, University, Therapy, ETH, Cancer, Research, Doctor of Philosophy, Trinity Hall, Cambridge, Chemistry, Entrepreneurship, Flagship Pioneering, Patient, Fellow, European Research Council, Atomic mass, Chemical biology, Library, Royal Society, Federal Institute of Science and Technology, Fine chemical, Pharmaceutical industry, Nursing, Spexy Beast

ALLSCHWIL, Switzerland, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company has appointed Gonçalo Bernardes, PhD, as acting Head of Chemical Biology.

Key Points: 
  • ALLSCHWIL, Switzerland, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company has appointed Gonçalo Bernardes, PhD, as acting Head of Chemical Biology.
  • “We are thrilled to welcome Gonçalo to Spexis, where we look forward to leveraging his expertise in chemical biology to advance the development of our novel macrocycle pipeline,” said Jeff Wager, M.D., Chairman & CEO of Spexis.
  • “Spexis remains committed to strengthening our leading position in macrocycle-based therapeutics with our two distinct and well characterized libraries, PEMFinder and MACROFinder.
  • Spexis continues to leverage its macrocycle platform into new therapeutic modalities and the company expects to provide further details on their progress later this year.